PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27089846-5 2016 In contrast to entacapone, tolcapone exhibited more potent inhibitory effects on UGT1A1, UGT1A7, and UGT1A10, while their inhibitory potentials against UGT1A9 were comparable. Tolcapone 27-36 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 81-87 27089846-4 2016 The results demonstrated that both tolcapone and entacapone exhibited inhibitory effects on UGT1A1, UGT1A7, UGT1A9 and UGT1A10. Tolcapone 35-44 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 92-98 27089846-6 2016 It is noteworthy that the inhibition constants (Ki) of tolcapone and entacapone against bilirubin-O-glucuronidation in human liver microsomes (HLM) are determined as 0.68muM and 30.82muM, respectively, which means that the inhibition potency of tolcapone on UGT1A1 mediated bilirubin-O-glucuronidation in HLM is much higher than that of entacapone. Tolcapone 55-64 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 258-264 27089846-7 2016 Furthermore, the potential risks of tolcapone or entacapone via inhibition of human UGT1A1 were quantitatively predicted by the ratio of the areas under the plasma drug concentration-time curve (AUC). Tolcapone 36-45 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 84-90 27089846-8 2016 The results indicate that tolcapone may result in significant increase in AUC of bilirubin or the drugs primarily metabolized by UGT1A1, while entacapone is unlikely to cause a significant DDI through inhibition of UGT1A1. Tolcapone 26-35 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 129-135